CTEC logo

Convatec Group PLC Stock Price

LSE:CTEC Community·UK£4.3b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author

CTEC Share Price Performance

UK£2.20
-0.46 (-17.26%)
UK£3.02
Fair Value
UK£2.20
-0.46 (-17.26%)
27.4% undervalued intrinsic discount
UK£3.02
Fair Value
Price UK£2.20
AnalystConsensusTarget UK£3.02

CTEC Community Narratives

·
Fair Value UK£3.02 27.4% undervalued intrinsic discount

Global Demographic Shifts And Emerging Markets Will Create Enduring Opportunity

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative

Trending Discussion

Updated Narratives

CTEC logo

CTEC: Advanced Wound Care Pipeline Will Support Future Rerating Potential

Fair Value: UK£3.02 27.4% undervalued intrinsic discount
18 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with reasonable growth potential.

3 Risks
3 Rewards

Convatec Group PLC Key Details

US$2.4b

Revenue

US$1.1b

Cost of Revenue

US$1.4b

Gross Profit

US$1.2b

Other Expenses

US$175.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 04, 2026
0.09
56.25%
7.18%
92.1%
View Full Analysis

About CTEC

Founded
1978
Employees
10910
CEO
Jonathan Mason
WebsiteView website
www.convatecgroup.com

Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson’s disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Recent CTEC News & Updates

Narrative Update Jun 22

CTEC: Advanced Wound Care Pipeline Will Support Future Rerating Potential

Convatec Group's analyst price targets have been trimmed, with recent moves such as Citi cutting its view to £2.30 from £2.50 and JPMorgan to £2.94 from £3.07, highlighting a more cautious stance even as analysts point to steady assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their updated models. Analyst Commentary Recent research on Convatec Group points to a mixed but engaged view from the Street, with some analysts trimming price targets while others make supportive adjustments that reflect differing opinions on valuation, execution and growth potential.
Narrative Update Jun 08

CTEC: Advanced Wound Care Pipeline And Ostomy Launch Will Support Future Rerating Potential

The analyst price target for Convatec Group has been revised downward to reflect recent Street research changes, including reductions to a range of approximately £2.30 to £2.94, along with updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent research on Convatec Group points to a more cautious stance on valuation, even as some analysts maintain a constructive view on the company’s execution and earnings potential.

Recent updates

No updates